TY - JOUR
T1 - Association of serum cytokines with oral HPV clearance
AU - Lam, Jennifer O.
AU - Bream, Jay H.
AU - Sugar, Elizabeth A.
AU - Coles, Christian L.
AU - Weber, Kathleen M.
AU - Burk, Robert D.
AU - Wiley, Dorothy J.
AU - Cranston, Ross D.
AU - Reddy, Susheel
AU - Margolick, Joseph B.
AU - Strickler, Howard D.
AU - Wentz, Alicia
AU - Jacobson, Lisa
AU - Guo, Yingshi
AU - Xiao, Weihong
AU - Gillison, Maura L.
AU - D'Souza, Gypsyamber
N1 - Funding Information:
We thank Palak Shah for cytokine testing, performed in the laboratory of Dr. Jay Bream at the Johns Hopkins Bloomberg School of Public Health. Oral rinse samples were processed and tested in the laboratory of Dr. Maura Gillison at The Ohio State University. Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS). MACS (Principal Investigators): Johns Hopkins University Bloomberg School of Public Health (Joseph Margolick), U01-AI35042; Northwestern University (Steven Wolinsky), U01-AI35039; University of California, Los Angeles (Roger Detels), U01-AI35040; University of Pittsburgh (Charles Rinaldo), U01-AI35041; the Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health (Lisa Jacobson), UM1-AI35043. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). The MACS website is located at http://aidscohortstudy.org/ . Data in this manuscript were also collected by the Women’s Interagency HIV Study (WIHS). WIHS (Principal Investigators): U01-AI-103408; Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590. The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH).
Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: Initial studies suggest higher serum levels of some pro-inflammatory cytokines may be associated with decreased cervical human papillomavirus (HPV) clearance. However, the relationship of cytokines with oral HPV clearance has not been explored. Methods: From 2010 to 2014, oral rinse and serum samples were collected semi-annually from 1601 adults. Oral rinse samples were tested for HPV DNA using PCR. Based on oral HPV results, 931 serum samples were selected for cytokine evaluation to include a roughly equal number of prevalent (n = 307), incident (n = 313), and no oral HPV infections (n = 311). Electrochemiluminescence multiplex assays were used to determine the concentrations of IL-6, IL-8, TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-10, IL-12 and IL-13. The relationship between serum cytokine concentrations (categorized into quartiles) and oral HPV clearance was evaluated with Wei-Lin-Weissfeld regression models, adjusting for HPV infection type (prevalent vs. incident), age, HIV status, and CD4 T cell count. Results: Higher TNF-α concentration was associated with decreased clearance in men (highest vs. lowest quartile, adjusted hazard ratio [aHR] = 0.52, 95% CI = 0.34-0.79) and women (aHR = 0.76, 95% confidence interval [CI] = 0.55-1.04), with stronger associations in men than women (p-interaction = 0.049). Higher IL-2 concentration was associated with reduced clearance in men (aHR = 0.69, 95% CI = 0.50-0.95), but not women (p-interaction = 0.058). Results were similar within CD4 T cell strata (CD4 ≥ 500 or CD4 < 500 cells/μl) among HIV-infected participants. No other cytokines were associated with clearance. Conclusion: High serum TNF-α is associated with reduced clearance of oral HPV infection.
AB - Background: Initial studies suggest higher serum levels of some pro-inflammatory cytokines may be associated with decreased cervical human papillomavirus (HPV) clearance. However, the relationship of cytokines with oral HPV clearance has not been explored. Methods: From 2010 to 2014, oral rinse and serum samples were collected semi-annually from 1601 adults. Oral rinse samples were tested for HPV DNA using PCR. Based on oral HPV results, 931 serum samples were selected for cytokine evaluation to include a roughly equal number of prevalent (n = 307), incident (n = 313), and no oral HPV infections (n = 311). Electrochemiluminescence multiplex assays were used to determine the concentrations of IL-6, IL-8, TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-10, IL-12 and IL-13. The relationship between serum cytokine concentrations (categorized into quartiles) and oral HPV clearance was evaluated with Wei-Lin-Weissfeld regression models, adjusting for HPV infection type (prevalent vs. incident), age, HIV status, and CD4 T cell count. Results: Higher TNF-α concentration was associated with decreased clearance in men (highest vs. lowest quartile, adjusted hazard ratio [aHR] = 0.52, 95% CI = 0.34-0.79) and women (aHR = 0.76, 95% confidence interval [CI] = 0.55-1.04), with stronger associations in men than women (p-interaction = 0.049). Higher IL-2 concentration was associated with reduced clearance in men (aHR = 0.69, 95% CI = 0.50-0.95), but not women (p-interaction = 0.058). Results were similar within CD4 T cell strata (CD4 ≥ 500 or CD4 < 500 cells/μl) among HIV-infected participants. No other cytokines were associated with clearance. Conclusion: High serum TNF-α is associated with reduced clearance of oral HPV infection.
KW - Infection
KW - Natural history
KW - Oral HPV
KW - Persistence
KW - TNF
UR - http://www.scopus.com/inward/record.url?scp=84962752977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962752977&partnerID=8YFLogxK
U2 - 10.1016/j.cyto.2016.04.002
DO - 10.1016/j.cyto.2016.04.002
M3 - Article
C2 - 27064455
AN - SCOPUS:84962752977
SN - 1043-4666
VL - 83
SP - 85
EP - 91
JO - Cytokine
JF - Cytokine
ER -